Gynecologic cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary

Nicholas Simon Reed, Eva Gomez-Garcia, Dolores Gallardo-Rincon, Brigitte Barrette, Klaus Baumann, Michael Friedlander, Ganessan Kichenadasse, Jae Weon Kim, Domenica Lorusso, Mansoor Raza Mirza, Isabelle Ray-Coquard

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms most commonly occurring in the gastrointestinal tract or the lungs. More frequent are gastrointestinal tumors, but over the past 30 years, there have been a number of small series or anecdotal case reports on ovarian NETs. Neuroendocrine tumors in the gynecologic tract are uncommon and account for about 2% of all gynecologic malignancies but may also be metastatic from other sites. They require a multimodality therapeutic approach determined by the extent of disease and the primary organ of involvement. Pathological diagnosis is critical to guide therapy. Surgery is the cornerstone of treatment for localized disease. There have been many new developments for treatment of advanced NETs including somatostatin analogs, hepatic artery embolization, chemotherapy, interferons, mammalian target of rapamycin inhibitors and radiolabeled somatostatin analogs. Given the rarity and lack of level I evidence, this is by nature more of a guidance and recommendation for management of these rare tumors until we can mount international studies.

Original languageEnglish (US)
Pages (from-to)S35-S41
JournalInternational Journal of Gynecological Cancer
Issue number9
StatePublished - Nov 2014


  • Carcinoid
  • Neuroendocrine
  • Ovarian
  • Somatostatin analogs

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology


Dive into the research topics of 'Gynecologic cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary'. Together they form a unique fingerprint.

Cite this